TESARO Company Profile (NASDAQ:TSRO)

About TESARO (NASDAQ:TSRO)

TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:TSRO
  • CUSIP: 88156910
  • Web: www.tesarobio.com
Capitalization:
  • Market Cap: $8.25 billion
  • Outstanding Shares: 53,864,000
Average Prices:
  • 50 Day Moving Avg: $144.83
  • 200 Day Moving Avg: $150.05
  • 52 Week Range: $36.71 - $192.94
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -35.63
  • P/E Growth: -0.71
Sales & Book Value:
  • Annual Revenue: $47.6 million
  • Price / Sales: 173.35
  • Book Value: $9.54 per share
  • Price / Book: 16.06
Profitability:
  • EBIDTA: ($398,820,000.00)
  • Net Margins: -798.68%
  • Return on Equity: -141.88%
  • Return on Assets: -79.30%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 11.59%
  • Quick Ratio: 11.38%
Misc:
  • Average Volume: 983,236 shs.
  • Beta: 1.51
  • Short Ratio: 7.63
 

Frequently Asked Questions for TESARO (NASDAQ:TSRO)

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($2.55) EPS for the quarter, missing the consensus estimate of ($2.26) by $0.29. The company earned $3.10 million during the quarter, compared to analysts' expectations of $3.84 million. TESARO had a negative return on equity of 141.88% and a negative net margin of 798.68%. TESARO's revenue was up 909.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.22) EPS. View TESARO's Earnings History.

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

20 brokerages have issued 1-year price targets for TESARO's shares. Their predictions range from $94.00 to $216.00. On average, they expect TESARO's stock price to reach $172.56 in the next year. View Analyst Ratings for TESARO.

What are analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • 1. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
  • 2. FBR & Co analysts commented, "On March 28, Galectin provided a summary of 4Q16 results and an update of its three clinical programs with GR-MD-02, GALT’s experimental galectin-3 inhibitor drug. While a top-line efficacy readout is not expected until 4Q17, our focus remains on the ongoing NASH-CX Phase IIb trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced cirrhosis. We still like GALT’s prospects for creating value with the advancement of NASH-CX; however, as GALT has limited funds to achieve its operational goals, we look for it to implement measures that rein in its high quarterly opex and preserve cash to ensure that NASH- CX remains on track in 2017." (4/3/2017)
  • 3. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (3/31/2017)
  • 4. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)
  • 5. Robert W. Baird analysts commented, "Earlier today, SOLO-2 data were presented at the SGO meeting, indicating AstraZeneca's Lynparza is comparable to Tesaro's niraparib in 2L+ ovarian cancer maintenance. Though only in gBRCA patients, these data suggest differences in efficacy among PARP's may be minimal. Next up is data from Clovis' Rubraca (ARIEL-3) in mid-2017, which will provide greater clarity on PARP competition in the non-gBRCA ovarian population. As we highlighted, with the PARP space shaping up to be less differentiated than initially thought, we reiterate our Neutral rating." (3/15/2017)

Who are some of TESARO's key competitors?

Who owns TESARO stock?

TESARO's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (19.16%), FMR LLC (15.00%), BlackRock Inc. (6.36%), Vanguard Group Inc. (5.44%), State Street Corp (1.85%) and BB Biotech AG (1.54%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Institutional Ownership Trends for TESARO.

Who sold TESARO stock? Who is selling TESARO stock?

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BB Biotech AG, Janus Capital Management LLC, Columbus Circle Investors, Marshall Wace LLP, OppenheimerFunds Inc., Alliancebernstein L.P. and Macquarie Group Ltd.. Company insiders that have sold TESARO stock in the last year include Edward C English, Grant C Bogle, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Insider Buying and Selling for TESARO.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Vanguard Group Inc., White Square Capital LLP, Neuberger Berman Group LLC, Candriam Luxembourg S.C.A. and AXA. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky, Enterprise Associates 13 L New and James O Armitage. View Insider Buying and Selling for TESARO.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of TESARO stock cost?

One share of TESARO stock can currently be purchased for approximately $153.19.

Analyst Ratings

Consensus Ratings for TESARO (NASDAQ:TSRO) (?)
Ratings Breakdown: 6 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $172.56 (12.64% upside)

Analysts' Ratings History for TESARO (NASDAQ:TSRO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Oppenheimer Holdings Inc.Initiated CoverageOutperform$183.00MediumView Rating Details
5/24/2017CannReiterated RatingOutperformMediumView Rating Details
5/10/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
5/11/2017Cowen and CompanyReiterated RatingHold$145.00MediumView Rating Details
5/10/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$202.00 -> $200.00MediumView Rating Details
4/22/2017Citigroup IncReiterated RatingBuy$232.00 -> $216.00LowView Rating Details
4/12/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$180.00LowView Rating Details
4/10/2017Janney Montgomery ScottInitiated CoverageNeutral -> Neutral$141.00LowView Rating Details
3/28/2017Morgan StanleyBoost Price TargetOverweight$182.00 -> $183.00HighView Rating Details
3/28/2017WedbushBoost Price TargetOutperform$164.00 -> $174.00HighView Rating Details
3/24/2017ArgusInitiated CoverageBuy$210.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
3/15/2017Robert W. BairdLower Price TargetPositive$182.00 -> $165.00MediumView Rating Details
3/2/2017Credit Suisse Group AGSet Price TargetBuy$151.00 -> $198.00N/AView Rating Details
2/17/2017Royal Bank of CanadaBoost Price TargetOutperform$142.00 -> $202.00N/AView Rating Details
2/9/2017SunTrust Banks, Inc.Reiterated RatingBuy -> Average$190.00N/AView Rating Details
1/19/2017Bank of America CorpBoost Price Target$149.26 -> $165.00N/AView Rating Details
11/7/2016Lake Street CapitalReiterated RatingBuy$114.00 -> $150.00N/AView Rating Details
11/4/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformN/AView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
6/30/2016Wells Fargo & CoReiterated RatingOutperformN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for TESARO (NASDAQ:TSRO)
Earnings by Quarter for TESARO (NASDAQ:TSRO)
Earnings History by Quarter for TESARO (NASDAQ:TSRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TESARO (NASDAQ:TSRO)
2017 EPS Consensus Estimate: ($8.49)
2018 EPS Consensus Estimate: ($3.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($2.39)($1.98)($2.20)
Q2 20175($3.10)($2.27)($2.67)
Q3 20175($2.39)($1.51)($1.93)
Q4 20175($2.22)($1.11)($1.69)
Q1 20181($1.29)($1.29)($1.29)
Q2 20181($1.07)($1.07)($1.07)
Q3 20181($0.79)($0.79)($0.79)
Q4 20181($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TESARO (NASDAQ:TSRO)
Insider Ownership Percentage: 40.50%
Institutional Ownership Percentage: 98.48%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.58View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.00View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.47View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.83View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.96View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.00View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.64View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for TESARO (NASDAQ:TSRO)
Latest Headlines for TESARO (NASDAQ:TSRO)
Source:
DateHeadline
americanbankingnews.com logoTESARO Inc (TSRO) Coverage Initiated by Analysts at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 25 at 8:51 AM
americanbankingnews.com logoCann Begins Coverage on TESARO Inc (TSRO)
www.americanbankingnews.com - May 24 at 5:16 PM
americanbankingnews.com logoTESARO Inc (TSRO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 6:20 PM
finance.yahoo.com logoTESARO, Inc. – Value Analysis (NASDAQ:TSRO) : May 18, 2017
finance.yahoo.com - May 19 at 6:23 PM
finance.yahoo.com logoTESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : May 17, 2017
finance.yahoo.com - May 17 at 12:31 PM
americanbankingnews.com logoFBR & Co Cuts TESARO Inc (TSRO) Price Target to $200.00
www.americanbankingnews.com - May 14 at 7:42 PM
americanbankingnews.com logoWedbush Research Analysts Increase Earnings Estimates for TESARO Inc (TSRO)
www.americanbankingnews.com - May 12 at 7:54 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for TESARO Inc Boosted by Analyst (TSRO)
www.americanbankingnews.com - May 12 at 7:54 AM
americanbankingnews.com logoTESARO Inc Forecasted to Post Q2 2017 Earnings of ($3.10) Per Share (TSRO)
www.americanbankingnews.com - May 12 at 7:54 AM
americanbankingnews.com logoTESARO Inc Forecasted to Earn Q2 2017 Earnings of ($2.59) Per Share (TSRO)
www.americanbankingnews.com - May 12 at 7:54 AM
americanbankingnews.com logoQ2 2017 Earnings Estimate for TESARO Inc Issued By Leerink Swann (TSRO)
www.americanbankingnews.com - May 12 at 7:54 AM
americanbankingnews.com logoLeerink Swann Research Analysts Cut Earnings Estimates for TESARO Inc (TSRO)
www.americanbankingnews.com - May 11 at 3:42 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Hold Rating for TESARO Inc (TSRO)
www.americanbankingnews.com - May 11 at 2:56 PM
americanbankingnews.com logoTESARO Inc (TSRO) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - May 11 at 9:09 AM
nasdaq.com logoEarnings Reaction History: TESARO, Inc., 100.0% Follow-Through Indicator, 5.1% Sensitive - Nasdaq
www.nasdaq.com - May 11 at 12:23 AM
americanbankingnews.com logoTESARO Inc (TSRO) Releases Earnings Results, Misses Estimates By $0.29 EPS
www.americanbankingnews.com - May 10 at 5:22 PM
finance.yahoo.com logoEdited Transcript of TSRO earnings conference call or presentation 9-May-17 8:15pm GMT
finance.yahoo.com - May 10 at 3:19 PM
finance.yahoo.com logoTesaro, Inc. (TSRO)
finance.yahoo.com - May 7 at 5:24 AM
americanbankingnews.com logoZacks: Brokerages Anticipate TESARO Inc (TSRO) Will Announce Quarterly Sales of $3.68 Million
www.americanbankingnews.com - May 5 at 3:32 PM
americanbankingnews.com logo-$2.24 Earnings Per Share Expected for TESARO Inc (TSRO) This Quarter
www.americanbankingnews.com - May 3 at 9:42 AM
americanbankingnews.com logoSomewhat Negative Press Coverage Very Likely to Affect TESARO (TSRO) Share Price
www.americanbankingnews.com - May 2 at 5:38 PM
streetinsider.com logoTESARO (TSRO) Submits IND Application for TSR-033 to FDA - StreetInsider.com
www.streetinsider.com - May 2 at 8:45 AM
streetinsider.com logoTESARO (TSRO) Submits IND Application for TSR-033 to FDA
www.streetinsider.com - May 1 at 10:42 AM
finance.yahoo.com logoTESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
finance.yahoo.com - May 1 at 10:42 AM
streetinsider.com logoTESARO (TSRO) Says Clinical Trial of TSR-042 has been ... - StreetInsider.com
www.streetinsider.com - April 29 at 8:26 PM
americanbankingnews.com logoFavorable Press Coverage Extremely Likely to Impact TESARO (TSRO) Stock Price
www.americanbankingnews.com - April 29 at 12:53 PM
streetinsider.com logoTESARO (TSRO) Says Clinical Trial of TSR-042 has been Expanded to Enroll Patients with MSI-H Endometrial Cancer
www.streetinsider.com - April 28 at 3:05 AM
finance.yahoo.com logoTESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
finance.yahoo.com - April 27 at 10:32 AM
streetinsider.com logoTESARO's (TSRO) VARUBY Approved by European Commission
www.streetinsider.com - April 26 at 9:54 PM
streetinsider.com logoTESARO's (TSRO) VARUBY Approved by European Commission - StreetInsider.com
www.streetinsider.com - April 26 at 4:50 PM
americanbankingnews.com logoTESARO (TSRO) Receives Daily News Impact Score of 0.17
www.americanbankingnews.com - April 26 at 12:11 PM
fool.com logoTesaro Inc Bulls Need a Reality Check -- The Motley Fool - Motley Fool
www.fool.com - April 26 at 8:39 AM
finance.yahoo.com logoTESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
finance.yahoo.com - April 26 at 8:39 AM
americanbankingnews.com logoTESARO Inc (TSRO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 25 at 5:44 PM
americanbankingnews.com logoTESARO (TSRO) Receives Media Sentiment Score of 0.27
www.americanbankingnews.com - April 23 at 11:25 AM
americanbankingnews.com logoCowen and Company Reaffirms "Market Perform" Rating for TESARO Inc (TSRO)
www.americanbankingnews.com - April 23 at 10:26 AM
americanbankingnews.com logoTESARO's (TSRO) "Buy" Rating Reiterated at Citigroup Inc
www.americanbankingnews.com - April 22 at 7:59 AM
marketwatch.com logoTesaro’s new ovarian drug will cost cancer patients $60,000 to $177,000 a year
www.marketwatch.com - April 21 at 10:47 AM
fool.com logoTesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing
www.fool.com - April 21 at 7:57 AM
finance.yahoo.com logoTesaro stock dives 7% after drug pricing snafu
finance.yahoo.com - April 20 at 10:55 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Extremely Likely to Affect TESARO (TSRO) Share Price
www.americanbankingnews.com - April 20 at 10:35 PM
streetinsider.com logoTESARO (TSRO) Says Zejula is Now Available in U.S.
www.streetinsider.com - April 20 at 11:39 AM
marketwatch.com logoTesaro drug pricing snafu sends stock down 3% and lifts rival drugmaker’s shares
www.marketwatch.com - April 20 at 10:23 AM
americanbankingnews.com logoTESARO (TSRO) Receives Daily Media Sentiment Score of 0.56
www.americanbankingnews.com - April 17 at 12:50 PM
americanbankingnews.com logoTESARO (TSRO) Receives Coverage Optimism Rating of 0.11
www.americanbankingnews.com - April 14 at 3:10 PM
americanbankingnews.com logoTESARO Inc (TSRO) Coverage Initiated by Analysts at Janney Montgomery Scott
www.americanbankingnews.com - April 14 at 7:14 AM
americanbankingnews.com logoTESARO Inc (TSRO) Research Coverage Started at Piper Jaffray Companies
www.americanbankingnews.com - April 13 at 11:14 PM
finance.yahoo.com logoThese 3 Stocks Have Tripled Over the Past Year
finance.yahoo.com - April 13 at 10:26 AM
americanbankingnews.com logo Analysts Expect TESARO Inc (TSRO) Will Post Earnings of -$2.21 Per Share
www.americanbankingnews.com - April 12 at 7:55 AM
americanbankingnews.com logoTESARO Inc (TSRO) Earns Neutral Rating from Analysts at Janney Montgomery Scott
www.americanbankingnews.com - April 10 at 9:24 AM

Social

Chart

TESARO (TSRO) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff